News
OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback